| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,244 | -4,761 |
| Depreciation | 21 | 17 |
| Reduction in the carrying amount of right-of-use assets | 299 | 196 |
| Share-based compensation | 345 | 268 |
| Allowance for doubtful accounts | 0 | 0 |
| Accounts receivable | 0 | 10 |
| Prepaid expenses and other current assets | -173 | -42 |
| Accounts payable | 528 | 741 |
| Accrued expenses and other current liabilities | 252 | 446 |
| Operating lease liability | -313 | -206 |
| Net cash used in operating activities | -4,939 | -3,267 |
| Purchase of property and equipment | 1 | 1 |
| Net cash used in investing activities | -1 | -1 |
| Proceeds from sales of common stock | 8,690 | 1,907 |
| Issuance costs of sale of common stock | 834 | 30 |
| Net cash provided by financing activities | 7,856 | 1,877 |
| Net change in cash and cash equivalents | 2,916 | -1,391 |
| Cash and cash equivalents at beginning of period | 2,371 | 2,371 |
| Cash and cash equivalents at end of period | 5,287 | 980 |
BioCardia, Inc. (BCDA)
BioCardia, Inc. (BCDA)